Scientific

Event Publication Document
MP0533 (CD33 x CD123 x CD70 x CD3), a tetra-specific CD3-engaging DARPin for the treatment of patients with relapsed/refractory AML or MDS/AML: results of an ongoing Phase 1/2a study
MP0621 (cKIT x CD16a x CD47), a multi-specific Switch-DARPin with conditional blockade of CD47, targeting hematopoietic stem cells: preclinical evaluation of a next-generation conditioning agent for stem cell transplantation
Recent Advances in Developing Radio-DARPin Therapeutics: ²¹²Pb-DLL3 for SCLC as a first program
Unlocking precision: a next-generation multi-specific CD3 Switch-DARPin with enhanced function to tackle current limitations of T cell engagers in ovarian cancer
Comprehensive biomarker analyses from a Phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic DARPin
Preclinical Assessment of 212Pb-Radio-DARPin Therapeutic (RDT) Targeting DLL3 in SCLC
C-KIT X CD16A X CD47 Switch-DARPin with Conditional Blockade of CD47: A Next-generation Targeted Conditioning for Hematopoietic Stem Cell Transplantation
212Pb-DLL3 Radio-DARPin shows promising Preclinical Antitumor Efficacy in Small Cell Lung Cancer
Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors
The DARPin antiviral ensovibep for non-hospitalized patients with COVID-19: Results from EMPATHY, a randomized, placebo-controlled Phase 2 study

Investors